| |
| |
|
| Insider
Information: |
Islam Saqib |
| Relationship: |
Director |
| City: |
Cheshire |
| State: |
CT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
320,302 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$7,999,018 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
320,302 |
|
|
| Total
Value |
$7,999,018 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -14.8%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alexion Pharmaceuticals Inc |
ALXN |
EVP, Chief Strat & Por... |
2016-02-29 |
43,799 |
2013-04-24 |
0 |
Premium* |
|
|
Springworks Therapeutics, Inc. |
SWTX |
Chief Executive Office... |
2024-01-08 |
256,264 |
|
0 |
Premium* |
|
|
Passage Bio, Inc. |
PASG |
Director |
2020-03-03 |
5,000 |
2020-03-03 |
0 |
Premium* |
|
|
Silverback Therapeutics, Inc. |
SBTX |
Director |
2020-12-03 |
15,239 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALXN |
Alexion Pharmaceuticals I... |
SVP, Chief Strat & Port. Off. |
• – – |
2014-11-03 |
4 |
S |
$190.50 |
$5,357,831 |
D/D |
(28,125) |
27,300 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2021-01-19 |
4 |
AS |
$78.54 |
$4,736,209 |
D/D |
(60,301) |
1,225,196 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2021-04-19 |
4 |
AS |
$69.04 |
$2,652,827 |
D/D |
(38,425) |
908,127 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
SVP, Chief Strat & Port. Off. |
• – – |
2014-11-03 |
4 |
OE |
$89.23 |
$2,509,594 |
D/D |
28,125 |
55,425 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2021-10-18 |
4 |
AS |
$58.59 |
$2,246,505 |
D/D |
(38,340) |
783,212 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2021-04-20 |
4 |
AS |
$66.39 |
$1,598,279 |
D/D |
(24,075) |
884,052 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Strat & Port. Off. |
• – – |
2015-04-27 |
4 |
S |
$181.57 |
$1,095,230 |
D/D |
(6,032) |
39,868 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2021-10-19 |
4 |
AS |
$58.81 |
$827,873 |
D/D |
(14,077) |
769,135 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2024-01-08 |
4 |
D |
$41.53 |
$743,553 |
D/D |
(17,904) |
256,264 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2021-10-20 |
4 |
AS |
$58.67 |
$591,527 |
D/D |
(10,083) |
779,218 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2024-01-05 |
4 |
D |
$37.96 |
$489,115 |
D/D |
(12,885) |
274,168 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2022-01-07 |
4 |
D |
$56.06 |
$330,362 |
D/D |
(5,893) |
851,695 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Strat & Port. Off. |
• – – |
2016-02-05 |
4 |
S |
$141.77 |
$282,661 |
D/D |
(1,970) |
46,178 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Strat & Port. Off. |
• – – |
2015-10-26 |
4 |
S |
$168.44 |
$262,430 |
D/D |
(1,558) |
38,310 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Strat & Port. Off. |
• – – |
2015-02-10 |
4 |
S |
$171.15 |
$256,725 |
D/D |
(1,500) |
34,560 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2023-01-06 |
4 |
D |
$27.52 |
$231,168 |
D/D |
(8,400) |
909,201 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2022-01-07 |
4/A |
D |
$56.06 |
$224,016 |
D/D |
(3,996) |
853,592 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Strat & Port. Off. |
• – – |
2016-02-08 |
4 |
S |
$138.02 |
$203,518 |
D/D |
(1,474) |
44,704 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Strat & Port. Off. |
• – – |
2015-12-08 |
4 |
AS |
$190.00 |
$180,500 |
D/D |
(950) |
36,385 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Strat & Port. Off. |
• – – |
2015-11-02 |
4 |
AS |
$180.00 |
$175,500 |
D/D |
(975) |
37,335 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2021-01-20 |
4 |
AS |
$78.75 |
$173,180 |
D/D |
(2,199) |
1,222,997 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Strat & Port. Off. |
• – – |
2016-02-29 |
4 |
S |
$138.91 |
$125,714 |
D/D |
(905) |
43,799 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Chief Executive Officer |
• • – |
2023-01-07 |
4 |
D |
$26.41 |
$108,202 |
D/D |
(4,097) |
905,104 |
0 |
- |
|
| PASG |
Passage Bio, Inc. |
Director |
– • – |
2020-03-03 |
4 |
B |
$18.00 |
$90,000 |
D/D |
5,000 |
5,000 |
2.39 |
% |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Strat & Port. Off. |
• – – |
2015-03-02 |
4 |
S |
$180.34 |
$41,118 |
D/D |
(228) |
39,432 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
